Identification of subgroup patients with stage IIIB/IV non-small cell lung cancer at higher risk for brain metastases

Lung Cancer

Volumn 82, Issue 2, 2013, Pages 319-323

  Hsiao, Shih Hsin ^a   Chung, Chi Li ^a,b   Chou, Yu Ting ^c   Lee, Hsin Lun ^d   Lin, Sey En ^a   Liu, H Eugene ^b,d  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Actuarial incidence of brain metastases; Adenocarcinoma; Early detection; Identification of subgroup patients at higher risk; Non small cell lung cancer; Young age

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ACTUARIAL INCIDENCE OF BRAIN METASTASES; ADENOCARCINOMA; EARLY DETECTION; IDENTIFICATION OF SUBGROUP PATIENTS AT HIGHER RISK; NON-SMALL CELL LUNG CANCER; YOUNG AGE;

ADULT; AGE FACTORS; AGED; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RISK FACTORS;

EID: 84887025000     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.08.004     Document Type: Article

References (27)

1. Sorensen J.B., Hansen H.H., Hansen M., Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988, 6:1474-1480.
2. Robnett T.J., Machtay M., Stevenson J.P., Algazy K.M., Hahn S.M. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol 2001, 19:1344-1349.
3. Moazami N., Rice T.W., Rybicki L.A., Adelstein D.J., Murthy S.C., DeCamp M.M., et al. Stage III non-small cell lung cancer and metachronous brain metastases. J Thorac Cardiovasc Surg 2002, 124:113-122.
4. Ceresoli G.L., Reni M., Chiesa G., Carretta A., Schipani S., Passoni P., et al. Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer 2002, 95:605-612.
5. Mujoomdar A., Austin J.H., Malhotra R., Powell C.A., Pearson G.D., Shiau M.C., et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology 2007, 242:882-888.
6. Hubbs J.L., Boyd J.A., Hollis D., Chino J.P., Saynak M., Kelsey C.R. Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer 2010, 116:5038-5046.
7. Lagerwaard F.J., Levendag P.C., Nowak P.J., Eijkenboom W.M., Hanssens P.E., Schmitz P.I. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999, 43:795-803.
8. Mehta M.P., Rodrigus P., Terhaard C.H., Rao A., Suh J., Roa W., et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003, 21:2529-2536.
9. Kalkanis S.N., Kondziolka D., Gaspar L.E., Burri S.H., Asher A.L., Cobbs C.S., et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96:33-43.
10. Gondi V., Mehta M.P. Novel insights into the management of brain metastases. Curr Opin Neurol 2010, 23:556-562.
11. Bhangoo S.S., Linskey M.E., Kalkanis S.N. Evidence-based guidelines for the management of brain metastases. Neurosurg Clin N Am 2011, 22:97-104. viii.
12. Minniti G., Salvati M., Muni R., Lanzetta G., Osti M.F., Clarke E., et al. Stereotactic radiosurgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer. Anticancer Res 2010, 30:3055-3061.
13. Bajard A., Westeel V., Dubiez A., Jacoulet P., Pernet D., Dalphin J.C., et al. Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma. Lung Cancer 2004, 45:317-323.
14. Butowski N. Medical management of brain metastases. Neurosurg Clin N Am 2011, 22:27-36. v-vi.
15. Li B., Yu J., Suntharalingam M., Kennedy A.S., Amin P.P., Chen Z., et al. Comparison of three treatment options for single brain metastasis from lung cancer. Int J Cancer 2000, 90:37-45.
16. Chang E.L., Wefel J.S., Hess K.R., Allen P.K., Lang F.F., Kornguth D.G., et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009, 10:1037-1044.
17. Davey P. Brain metastases: treatment options to improve outcomes. CNS Drugs 2002, 16:325-338.
18. Ortuzar W., Hanna N., Pennella E., Peng G., Langer C., Monberg M., et al. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer. Clin Lung Cancer 2012, 13:24-30.
19. Omuro A.M., Kris M.G., Miller V.A., Franceschi E., Shah N., Milton D.T., et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005, 103:2344-2348.
20. Heon S., Yeap B.Y., Britt G.J., Costa D.B., Rabin M.S., Jackman D.M., et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 2010, 16:5873-5882.
21. Kerr K.M. Personalized medicine for lung cancer: new challenges for pathology. Histopathology 2012, 60:531-546.
22. Cooper W.A., O'Toole S., Boyer M., Horvath L., Mahar A. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology 2011, 43:103-115.
23. Franceschi E., Brandes A.A. Brain metastases from non-small-cell lung cancer: is there room for improvement. Expert Rev Anticancer Ther 2012, 12:421-423.
24. Monaco E.A., Faraji A.H., Berkowitz O., Parry P.V., Hadelsberg U., Kano H., et al. Leukoencephalopathy after whole-brain radiation therapy plus radiosurgery versus radiosurgery alone for metastatic lung cancer. Cancer 2013, 119:226-232.
25. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
26. Thomas R., Wolf J. Personalized therapy of lung cancer. Onkologie 2012, 35(Suppl. 1):14-19.
27. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136:260-271.